TNF-alpha inhibitors in Systemic Lupus Erythematosus. A case report and a systematic literature review

Abstract Joint involvement is a common manifestation of systemic lupus erythematosus (SLE) and is described as a non-erosive mild synovitis. However some SLE patients may present a more severe joint involvement requiring aggressive therapy. We describe the case of a SLE patient with a severe arthrit...

Full description

Saved in:
Bibliographic Details
Published in:Modern rheumatology 2015-07, Vol.25 (4), p.642-645
Main Authors: Mosca, Marta, Tani, Chiara, Filice, Maria Elena, Carli, Linda, Delle Sedie, Andrea, Vagnani, Sabrina, Della Rossa, Alessandra, Baldini, Chiara, Bombardieri, Stefano
Format: Article
Language:English
Subjects:
Adult
Arthritis
Certolizumab Pegol - therapeutic use
Female
Humans
Immunosuppressive Agents - therapeutic use
Lupus
Lupus Erythematosus, Systemic - drug therapy
Medical treatment
Rheumatology
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor Necrosis Factor-alpha - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Joint involvement is a common manifestation of systemic lupus erythematosus (SLE) and is described as a non-erosive mild synovitis. However some SLE patients may present a more severe joint involvement requiring aggressive therapy. We describe the case of a SLE patient with a severe arthritis unresponsive to methotrexate, successfully treated with anti-TNF-alpha drug as induction therapy and we report the results of a systematic literature review on the use of TNF-alpha inhibitors in SLE.
ISSN:1439-7595
1439-7609
DOI:10.3109/14397595.2013.844306